In 1914 the German cytologist Theodor Boveri coined the phrase “Cancer is a disease of the genome”. At this time his ideas were equally revolutionary as they were highly contested. Fast forward. More than hundred years later, Next-Generation Sequencing effectively permits a highly sensitive analysis of cancer cells. It can help us to understand mutations associated with cancer development and progression. It also reveals other genomic rearrangements previously unknown to occur in the cancer genome. Translation of these findings for clinical purposes is increasingly part of standard care today. I fully believe that next-generation sequencing will rapidly become a powerful tool for the personalized diagnosis and management of cancer. This e-book will focus on the parts of this process that are best understood: Cancer Gene Panels.
Detecting cancer at an early stage can make it much more treatable. Developing tests and making them clinically actionable is crucial to beat this disease. Hence, we came out with a new eBook covering the state of the art of gene panel tests for cancer. Of course there is more that can be done. The field is pushing into exome, whole genome and RNA sequencing to provide to capture more of the complex processes behind oncogenisis.
With VarSeq, Golden Helix has developed a software platform that supports gene panel analysis today leading to clinically actionable information. It also provides a framework allowing you to conduct whole exome and genome analysis as part of your ongoing research work. VarSeq is designed to be a crucial part of the bioinformatics pipeline of any testing lab.
Important links:
Download the eBook here!
Request a free trial for VarSeq here!
About Andreas Scherer
Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from next-generation sequencing. With its solutions, hundreds of the world’s hospitals and testing labs are able to harness the full potential of genomics to identify the cause of disease, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in thousands of peer-reviewed publications. Golden Helix is also on the Inc 5000 list of the fastest-growing private companies in the US.
He is also Managing Partner of Salto Partners, Inc, a management consulting firm headquartered in Nevada. He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales, and operations. Clients are operating in the high-tech and life sciences space.
Dr. Scherer holds a Ph.D. in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards!
View all posts by Andreas Scherer →
